Erenumab for migraine prevention in a patient with mitochondrial encephalopathy, lactate acidosis, and stroke‐like episodes syndrome: A case report
Abstract
1Department of Neurology, Martin Luther University HalleWittenberg, University Hospital Halle, Halle (Saale), Germany 2Department of Neurology, West German Headache Center, University of DuisburgEssen, Essen, Germany 3Department of Radiology, Martin Luther University HalleWittenberg, University Hospital Halle, Halle (Saale), Germany 4Department of Neurology, St. Georg Hospital Leipzig, Leipzig, Germany
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Bioactive Molecules Released in Food by Lactic Acid Bacteria: Encrypted Peptides and Biogenic Amines
- A central role for amyloid fibrin microclots in long COVID/PASC: origins and therapeutic implications
- Bioaccessibility and bioavailability of phenolic compounds
- The Glutamate Hypothesis in ALS: Pathophysiology and Drug Development
- Therapeutic Approaches to Genetic Ion Channelopathies and Perspectives in Drug Discovery
- Effects of the Mediterranean Diet on the Components of Metabolic Syndrome Concerning the Cardiometabolic Risk
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.